BUSINESS

JCR, Teijin Launch Japan PI/PII of Regenerative Medicine Product for Cerebral Infarction

February 7, 2019
JCR Pharmaceuticals and Teijin said on February 6 that the first patient has received dosing in PI/II studies of JTR-161, an allogeneic regenerative medicine product made up of dental pulp-derived stem cells (DPCs), in Japan for the treatment of cerebral…

To read the full story

Related Article

BUSINESS

By Reiji Anasako

Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…

Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…

By Takashi Ebisawa

A series of drug makers restructured or sold off production facilities in FY2018. Others dissolved or withdrew from the pharmaceutical business altogether. The entry of generics and transfer of products triggered these moves, but the underlying factor was the impact…

By Philip Carrigan

With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…